[Substitution therapy with prothrombin complex concentrates in acquired coagulation disorders]

Area of Science:

• Hematology
• Transfusion Medicine

Background:

• Acquired coagulation disorders, particularly prothrombin complex deficiencies (factors II, VII, IX, X), necessitate effective treatment.
• Patients on oral anticoagulation or with liver disease often require prothrombin complex concentrates for bleeding or procedures.

Purpose of the Study:

• To evaluate the efficacy and safety of Prothromblex500 and Prothromblex Total500 in treating acquired coagulation disorders.
• To assess the use of these plasma concentrates in patients undergoing surgery, diagnostic procedures, or experiencing severe bleeding.

Main Methods:

• Retrospective analysis of 246 patients treated with Prothromblex500 or Prothromblex Total500 over 11 years.
• Monitoring of coagulation parameters and clinical outcomes, including bleeding episodes, surgical procedures, and side effects.

Main Results:

• Both plasma concentrates demonstrated adequate correction of abnormal coagulation.
• Effective control of bleeding and successful completion of procedures without hemorrhagic complications were observed.
• Better results were noted in patients on oral anticoagulation compared to those with severe liver disease.

Conclusions:

• Prothromblex500 and Prothromblex Total500 are safe and effective for managing acquired coagulation disorders.
• These concentrates provide reliable substitution therapy for patients with prothrombin complex deficiencies, including those on anticoagulation or with liver disease.
• No adverse events, such as intravascular coagulation, were reported during the study period.